Choksi Laboratories Limited carries a market capitalization of 849.76M, placing it among publicly traded companies globally. Its enterprise value stands at 1.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 849.76M |
| Enterprise Value | 1.06B |
Choksi Laboratories Limited currently has 6.97M shares outstanding.
| Shares Outstanding | 6.97M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Choksi Laboratories Limited trades at a trailing price-to-earnings ratio of 36.66. The price-to-sales ratio is 1.57, and the price-to-book ratio stands at 10.34.
| PE Ratio | 36.66 |
| PS Ratio | 1.57 |
| PB Ratio | 10.34 |
| P/TBV Ratio | 2.86 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, Choksi Laboratories Limited trades at an EV/EBITDA multiple of 20.80 and an EV/FCF ratio of 61.06. The EV/Sales ratio of 2.30 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.80 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.30 |
| EV / EBITDA | 20.80 |
| EV / EBIT | 20.80 |
| EV / FCF | 61.06 |
Choksi Laboratories Limited maintains a current ratio of 0.82, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 133.60, indicating elevated leverage, while an interest coverage ratio of 1.81 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.82 |
| Quick Ratio | 0.02 |
| Debt / Equity | 133.60 |
| Debt / EBITDA | 6.72 |
| Interest Coverage | 1.81 |
Choksi Laboratories Limited posts a return on equity of 28.20 and a return on invested capital of 5.56.
| Return on Equity (ROE) | 28.20 |
| Return on Assets (ROA) | 2.86 |
| Return on Invested Capital (ROIC) | 5.56 |
| Return on Capital Employed (ROCE) | 9.57 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 19.73 |
Over the trailing twelve months, Choksi Laboratories Limited has paid 12.30M in income taxes, reflecting an effective tax rate of 38.51.
| Income Tax | 12.30M |
| Effective Tax Rate | 38.51 |
Choksi Laboratories Limited's stock has declined approximately -33.20558% over the past 52 weeks. The 50-day moving average sits at 116.49, while the 200-day moving average is 125.17.
| Beta (5Y) | N/A |
| 52-Week Price Change | -33.20558% |
| 50-Day Moving Average | 116.49 |
| 200-Day Moving Average | 125.17 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Choksi Laboratories Limited generated 460.06M in revenue and converted that into 19.64M in net income, yielding earnings per share of 2.83. EBITDA reached 50.85M, while operating income came in at 50.85M.
| Revenue | 460.06M |
| Gross Profit | 381.74M |
| Operating Income | 50.85M |
| Pretax Income | 31.95M |
| Net Income | 19.64M |
| EBITDA | 50.85M |
| EBIT | 50.85M |
| Earnings Per Share (EPS) | 2.83 |
Choksi Laboratories Limited holds 4.28M in cash and equivalents against 341.70M in total debt, resulting in a net debt position of 299.72M. Total book value stands at 69.65M, with working capital of -42.21M providing operational flexibility.
| Cash & Cash Equivalents | 4.28M |
| Total Debt | 341.70M |
| Net Debt | 299.72M |
| Equity (Book Value) | 69.65M |
| Book Value Per Share | 10.02 |
| Working Capital | -42.21M |
Choksi Laboratories Limited operates with a gross margin of 82.98, reflecting its pricing power and cost economics. The operating margin of 11.05 and net profit margin of 4.27 provide insight into operational efficiency.
| Gross Margin | 82.98 |
| Operating Margin | 11.05 |
| Pretax Margin | 6.94 |
| Profit Margin | 4.27 |
| EBITDA Margin | 11.05 |
Choksi Laboratories Limited posts an Altman Z-Score of 1.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.74 |